Incyte Corporation Total Assets
Incyte Corporation total assets. Based on the latest financial reports, Incyte Corporation (INCY) holds total assets worth $7.87 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see INCY market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Incyte Corporation (1993–2025)
Total assets of Incyte Corporation from 1993 to 2025. This chart illustrates how Incyte Corporation's total assets have evolved over time, based on quarterly financial data. See INCY stock price and chart for real-time trading data and today's change.
Incyte Corporation - Asset Composition Analysis
Incyte Corporation Total Assets Breakdown (December 2025)
Incyte Corporation total assets breakdown as of December 2025. Incyte Corporation's total assets of $7.87 Billion consist of 72.2% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.5% |
| Accounts Receivable | $1.02 Billion | 14.7% |
| Inventory | $101.06 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $117.13 Million | 1.7% |
| Goodwill | $133.00 Million | 1.9% |
Asset Composition Trend (1993–2025)
This chart illustrates how Incyte Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Incyte Corporation's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Incyte Corporation's current assets represent 72.2% of total assets in 2025, a decrease from 89.2% in 1993.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2025, down from 88.1% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 14.7% of total assets.
Incyte Corporation Competitors by Total Assets
Key competitors of Incyte Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Incyte Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.66 | 2.85 | 3.94 |
| Quick Ratio | 4.58 | 2.78 | 3.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.81 Billion | $2.37 Billion | $2.18 Billion |
Incyte Corporation - Advanced Valuation Insights
This section examines the relationship between Incyte Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.89 |
| Latest Market Cap to Assets Ratio | 3.43 |
| Asset Growth Rate (YoY) | 27.8% |
| Total Assets | $6.96 Billion |
| Market Capitalization | $23.84 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Incyte Corporation's assets at a significant premium (3.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Incyte Corporation's assets grew by 27.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Incyte Corporation (1993–2025)
The table below shows the annual total assets of Incyte Corporation from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.96 Billion | +27.80% |
| 2024-12-31 | $5.44 Billion | -19.73% |
| 2023-12-31 | $6.78 Billion | +16.11% |
| 2022-12-31 | $5.84 Billion | +18.40% |
| 2021-12-31 | $4.93 Billion | +38.54% |
| 2020-12-31 | $3.56 Billion | +3.92% |
| 2019-12-31 | $3.43 Billion | +29.52% |
| 2018-12-31 | $2.65 Billion | +14.90% |
| 2017-12-31 | $2.30 Billion | +40.52% |
| 2016-12-31 | $1.64 Billion | +62.65% |
| 2015-12-31 | $1.01 Billion | +21.37% |
| 2014-12-31 | $830.07 Million | +31.85% |
| 2013-12-31 | $629.57 Million | +90.54% |
| 2012-12-31 | $330.42 Million | +0.44% |
| 2011-12-31 | $328.96 Million | -32.81% |
| 2010-12-31 | $489.58 Million | -31.28% |
| 2009-12-31 | $712.39 Million | +206.55% |
| 2008-12-31 | $232.39 Million | -15.71% |
| 2007-12-31 | $275.69 Million | -22.03% |
| 2006-12-31 | $353.60 Million | -5.48% |
| 2005-12-31 | $374.11 Million | -27.63% |
| 2004-12-31 | $516.92 Million | +36.19% |
| 2003-12-31 | $379.55 Million | -31.26% |
| 2002-12-31 | $552.14 Million | -21.74% |
| 2001-12-31 | $705.56 Million | -20.44% |
| 2000-12-31 | $886.82 Million | +299.65% |
| 1999-12-31 | $221.90 Million | -3.65% |
| 1998-12-31 | $230.30 Million | +19.26% |
| 1997-12-31 | $193.10 Million | +188.64% |
| 1996-12-31 | $66.90 Million | +15.74% |
| 1995-12-31 | $57.80 Million | +101.39% |
| 1994-12-31 | $28.70 Million | +63.07% |
| 1993-12-31 | $17.60 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more